Xilio Therapeutics Announces Inducement Grants

Biotech firm issues stock options to new employees under Nasdaq rules

Apr. 3, 2026 at 9:06pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a sleek, modern computer mouse, a brushed metal pen, and a stack of crisp white business cards arranged elegantly on a clean, monochromatic seamless background, conceptually representing the abstract ideas of corporate strategy, finance, and innovation.Xilio Therapeutics' latest inducement grants signal the biotech firm's continued growth and investment in top talent.Waltham Today

Xilio Therapeutics, a clinical-stage biotechnology company, announced that it has granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under the company's 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.48 per share and will vest over time as the employees continue their service with the company.

Why it matters

Inducement grants like these are common in the biotech industry as a way to attract and retain top talent. Xilio's announcement demonstrates the company's continued growth and investment in expanding its workforce to advance its pipeline of masked immuno-oncology therapies.

The details

The stock options granted by Xilio Therapeutics have a ten-year term and will vest as to 25% of the shares on the first anniversary of the employee's start date, with the remaining 75% vesting in 36 equal monthly installments thereafter. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to issue inducement awards to new employees without shareholder approval.

  • The stock options were granted effective April 1, 2026.

The players

Xilio Therapeutics, Inc.

A clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer.

Got photos? Submit your photos here. ›

The takeaway

Xilio's inducement grants demonstrate the company's commitment to expanding its workforce and advancing its pipeline of innovative cancer treatments. As the biotech industry continues to grow, these types of talent acquisition strategies will likely become increasingly common.